Early Prediction of Pathology Response of Chemoradiotherapy With FLT PET
Status:
Terminated
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
The goal of this research study is to learn if a new type of PET scan (18F-FLT) can help to
better detect changes of tumor growth rate (or how active) in esophagus cancer and lung
cancer Researchers will study at what time during treatment the 18F-FLT PET scan should be
given to get the best results. A Positron Emission Tomography (PET) scan is a type of scan
that uses a radioactive solution to locate cancer cells inside the body. Using the PET scan,
doctors can locate solid tumors and collect information about how "active" the cancer cells
are. For this study, a new type of solution, [F-18]-fluoro-L-thymidine (FLT), will be used.
FLT can detect actively growing tumor, and researchers hope that FLT may be able to help
provide information about how well esophagus cancer treatment is working. This information
could be used to help predict if the cancer will respond to treatment.
All enrolled subjects will receive PET/CT imaging at pre-Neoadjuvant Therapy and post-3 weeks
Neoadjuvant Therapy (3 weeks from the start of Neoadjuvant Therapy) prior to the surgery. At
each time of the PET/CT procedure, the subject will receive an injection of FLT which is an
investigational pharmaceutical labeled with radioactive fluorine. 45-60 mines after the FLT
injection, the scan will be performed. Each scan might take 10-15 minutes. Participation in
this pilot study will not change the patients normal chemotherapy, radiation treatment, and
surgery recommended the patients physician as parts of their standard of care.